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UTILIZATION OF PROTON PUMP INHIBITORS IN COMBINATION REGIMEN 
FOR BREAST CANCER TREATMENT BY TARGETING FATTY ACID SYNTHASE 
 
   Fatty acid synthase (FASN) over-expression has been associated with poor prognosis and 
recurrence in cancer patients. In addition, it has also been found that overexpression of 
FASN causes resistance to DNA-damaging treatments by up-regulating the non-
homologous end joining (NHEJ) repair of DNA double-strand break. 
   Proton pump inhibitors (PPIs), were originally designed to decrease gastric acid 
production by binding irreversibly with gastric hydrogen potassium ATPase. PPIs have 
recently been reported to reduce drug resistance in cancer cells when used in combination 
with other chemotherapeutics, although the mechanism of resistance reduction is uncertain. 
In our lab, previous investigation showed that PPIs decreased FASN thioesterase (TE) 
domain activity and cancer cell proliferation in a dose-dependent manner.  
   In this study, I tested the hypothesis that PPIs sensitize breast cancer cells to doxorubicin 
and ionizing radiation (IR) treatments by inhibiting FASN. When administered to breast 
cancer cells as single-agent, lansoprazole exhibited the highest potency in inhibiting both 
FASN activity and breast cancer cell proliferation, among four PPIs tested. In addition, 
treatment of breast cancer cells with lansoprazole decreased the mRNA and protein levels 
of poly (ADP-ribose) polymerase-1 (PARP-1) and NHEJ activity, accompanied by elevated 
γ-H2AX expression. Following a 3-day treatment with lansoprazole, a dose-dependent 
disruption in cell cycle disruption and increased apoptosis were also detected. Combination 
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of lansoprazole with either doxorubicin or IR caused profoundly higher levels of DNA 
damage accumulation than doxorubicin or IR treatment alone, suggesting synergistic 
effects.  
   Taken together, our observations suggest that PPIs synergistically suppress breast cancer 
cells in combination with DNA damaging treatments by inhibiting FASN. These findings 
may provide a potential route to overcome resistance to DNA-damaging chemo/radiation 
treatments in refractory breast cancers.  
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Introduction 
A. Brief overview of fatty acid synthase 
   Fatty acid synthase (FASN), a 270-kDa homodimeric enzyme, is the sole mammalian 
enzyme involved in de novo lipid biosynthesis. It is a seven-domain enzyme that catalyzes 
the synthesis of saturated long-chain fatty acids, mainly 16-carbon palmitate, from acetyl 
CoA and malonyl CoA, utilizing nicotinamide adenine dinucleotide phosphate (NADPH) 
as reducing agent [1-4]. Lipids play important roles in energy metabolism and storage, also 
as signaling molecules, including sterols, isoprenoids, acylglycerols and phospholipids [5-
8]. De novo fatty acid biosynthesis is largely repressed by dietary fat in normal tissues, 
restricted mainly to lipogenic tissue, liver, and lactating breast. In contrast, cancer cells are 
often found to have elevated FASN expression and activity, which could be a response to 
the high metabolic demand and low availability of serum-derived lipids in the tumor 
microenvironment [5-13]. Numerous studies have shown that highly activated FASN was 
found in many cancer types compared with normal tissues, notably in breast cancers [14-
19]. Fatty acid synthesis is crucial for cancer cell development, growth, maintenance and 
survival. Moreover, FASN over-expression has also been associated with poor prognosis 
and recurrence in cancer patients [20, 21]. 
   In our lab, it has been found that overexpression of FASN contributes to resistance to 
DNA-damaging treatments, such as doxorubicin, mitoxantrone, etoposide, and ionizing 
radiation (IR). Later studies showed that FASN regulated cellular response against 
genotoxic insults by up-regulating poly (ADP-ribose) polymerase-1 (PARP-1) and DNA 
repair. Overexpression of FASN suppressed NF-κB but increased SP1 expression. SP1 
competes with NF-κB in binding to the composite element of the PARP-1 promoter and 
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led to up-regulation of PARP-1. PARP-1 increased Ku protein recruitment and DNA repair 
activity. Lipid deprivation had no effect on NF-κB but suppressed SP1 expression, which 
could be rescued by palmitate supplementation [22-24].  
 
B. Brief overview of PARP and DNA repair 
   Poly (ADP-ribose) polymerases (PARPs) are ADP-ribosyl transferase enzymes that 
transfer negatively charged ADP-ribose groups to itself and other target proteins from 
donor NAD+, a process called PARylation. Through PARylation, PARPs play crucial roles 
in a variety of cellular processes, such as transcriptional regulation, RNA interference, 
mitochondrial function, formation of subnuclear bodies and cell division, most prominently 
in DNA damage response (DDR). In humans, PARP-1, the most characterized member of 
the PARP superfamily accounts for more than 90% of overall cellular PARylation activity 
in response to DNA damage. At sites of DNA breaks, autoPARylation of PARP serves as a 
signal and recruits DNA repair machinery to the damage site to activate DNA repair 
processes. Accumulation of negative charges from autoPARylation drives PARP to 
dissociate from DNA, which is required for DNA repair completion [25-27]. 
   PARP has been demonstrated to be involved in most DNA repair pathways, including 
base excision repair (BER), homologous recombination (HR), and non-homologous end 
joining (NHEJ) processes. NHEJ, despite its error-prone nature and elevated inaccuracy, is 
the predominant repair pathway for double-strand breaks (DSBs) in mammalian cells for 
its rapid repair activity and being active throughout the cell cycle [28]. There are 
accumulating reports showing that PARP-1 acts as sensors of DSBs in the genome by 
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binding to the break and recruiting different downstream repair proteins of both the HR 
and NHEJ pathways [24, 29]. 
 
C. Brief overview of FASN inhibitors and proton pump inhibitors 
   FASN was first identified as tumor antigen OA519 in aggressive breast cancers in 1994 
[30]. Over the past twenty years, the importance of fatty acid biosynthesis for cancer cell 
growth and survival has been shown in numerous studies, and many different inhibitors of 
FASN have been developed and evaluated, such as cerulenin [30-32], C75 [33-38], orlistat 
[39-41], and triclosan [42-44]. Despite the promising potential of FASN as a target against 
cancers, there is only one FASN inhibitor, TVB-2640, that entered clinical trial [45]. The 
difficulty in selectively inhibiting fatty acid biosynthesis in cancer cells without dramatic 
systemic effects was a major issue that needs to be conquered. To search for novel 
inhibitors of FASN while minimizing unwanted side effects, our lab tried to reposition 
FDA-approved drugs, which are well-studied in patients, as FASN inhibitors. Virtual 
DOCK screening of FDA-approved drugs followed by a fluorogenic assay using 
recombinant thioesterase (TE) protein led to the finding that proton pump inhibitors (PPIs) 
competitively inhibited FASN TE activity [46].  
   PPIs, among the most widely sold drugs in the world, effectively reduce stomach acid 
production. They are OTC drugs and generally well tolerated in human. PPIs are prodrugs 
which are activated by acid, and bind covalently to the gastric H+, K+-ATPase via disulfide 
bond [47]. Recently, PPIs have been reported to sensitize cancer cells when used in 
combination with other chemotherapeutics, although the mechanism of action is uncertain 
[48-53].  
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   Previous study in our lab showed that PPIs were able to decrease FASN activity and 
cancer cell proliferation [46]. In this study, the objective was to expand our studies focused 
on  the effectiveness of PPIs in targeting FASN in breast cancer cells. In addition, how PPIs 
mechanistically impact PARP-1 level and DNA repair activity through FASN inhibition 
was further investigated. Finally, the most potent PPI identified in this study was evaluated 
in combination with standard-of-care DNA-damaging agents used to treat breast cancer to 

















Materials and Methods 
A. Materials 
   Cell culture mediums Opti-MEM and fetal bovine serum were purchased from Life 
technologies (Grand Island, NY). DMEM, trypsin-versene mixture, and 
Antibiotic/Antimycotic solution 100x were purchased from Mediatech (Manassas, VA), 
Lonza (Walkersville, MD) or GE (Logan, UT). pGL3 Luciferase Reporter Vectors, 
pRL Renilla Luciferase Control Reporter Vectors, and Dual-Luciferase Reporter Assay 
System were purchased from Promega (Madison, WI). All electrophoresis reagents, 
polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad (Hercules, 
CA). Lansoprazole, omeprazole, pantoprazole, rabeprazole, doxorubicin, PMSF, 
dithiothreitol (DTT), and propidium iodide (PI) were purchased from Sigma (St. Louis, 
MO). Annexin V-FITC apoptosis detection kit was purchased from Millipore (Billerica, 
MA). Olaparib was purchased from LC Laboratories (Woburn, MA). SYBR Green PCR 
master Mix for rt-qPCR was purchased from Applied Biosystems (Foster City, CA). 
Monoclonal antibody against fatty acid synthase (FASN) was purchased from BD 
Biosciences (San Jose, CA). Antibodies to PARP-1, was purchased from Cell Signaling 
(Danvers, MA). γ-H2AX antibody was purchased from Millipore (Billerica, MA). 
Lipofectamine 2000 and G418 were purchased from Life technologies (Grand Island, NY). 
ECL Western Blotting detection reagents and SuperSignal West Dura extended duration 
substrate were purchased from GE Healthcare (Pittsburg, PA) and Thermo Scientific 
(Rockford, IL), respectively. MCF7, MDA-MB-468, and MDA-MB-231 cells were 
purchased from ATCC (Manassas, VA). T47D cells were generously provided by Dr. 
Brittney-Shea Herbert (IUSM). 
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B. Cell culture 
   Human breast cancer cell line MCF7, T47D, MDA-MB-468, and MDA-MB-231 were 
cultured at 37 °C with 5% CO2 in DMEM medium, supplemented with 10% fetal bovine 
serum and 1x Antibiotic/Antimycotic solution. FASN-overexpressing MCF7 clones 
(MCF7/FASN) and its vector-transfected control clones (MCF7/Vec) were maintained in 
DMEM medium supplemented with 10% fetal bovine serum, 1x Antibiotic/Antimycotic 
solution, and 400 μg/ml G418. Doxorubicin resistance stable clones MCF7/AdVp3000 
with FASN-knockdown (M3k/SiFASN) and its control scrambled shRNA-transfected 
clone (M3k/Scr) were maintained in DMEM medium supplemented with 10% fetal bovine 
serum, 1x Antibiotic/Antimycotic solution, 400 μg/ml G418, and 3000 ng/L doxorubicin. 
G418 and doxorubicin were not included in the experimental treatment media. 
 
C. Western blot analysis 
   Cells were harvested and then lysed in TNN buffer (50 mM Tris-HCl, 150 mM NaCl, 
0.5 % NP-40, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO3, with 1 mM PMSF and 1 mM 
DTT, added immediately before use, pH = 7.4) for 30 min on ice with occasional agitation. 
After brief sonication, lysate was harvested and centrifuged at 13,000 g for 15 minutes at 
4 oC to remove insoluble pellet. Protein concentration of cell lysate was determined using 
Bio-Rad protein assay kit. Cell lysates were resolved by SDS-PAGE followed by 
transferring to a polyvinylidene fluoride membrane. The blot was then probed with 
antibodies as follows: Fatty Acid Synthase (610963, BD biosciences), PARP-1 (46D11, 
CST), β-actin (A2228, Sigma), γ-H2AX (05-636, Millipore) and horseradish peroxidase–
conjugated secondary antibodies (Sigma). The signal was captured by X-ray films after 
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incubation with Amersham ECL Western Blotting Detection Reagent (RPN2106, GE). X-
ray films were scanned and quantified with ImageJ. 
 
D.  FASN activity assay 
   FASN holoenzyme activity was measured by NADPH oxidation of fatty acid synthesis 
as previously described [54]. From a group of four breast cancer cell lines, MCF7 lysate 
was chosen to test FASN activity for its high FASN expression level. MCF7 cells were 
detached by digestion with Trypsin + EDTA (0.05%), washed with PBS and resuspend in 
ice-cold PBS buffer containing 1 mM DTT, 1 mM EDTA, and 0.05% Brij35. After brief 
sonication, lysate was harvested and centrifuged at 13,000 g for 15 minutes at 4 oC to 
remove insoluble pellet. Protein concentration of cell lysate was determined using Bio-Rad 
protein assay kit. In each well of a 96-well flat bottom plate, 250 µg total protein was used 
in 200 µL reaction consisting of 200 mM K2HPO4 pH6.8, 1 mM DTT, 1 mM MgCl2, 240 
µM NADPH, and 30 µM Acetyl-CoA. After incubation with various concentrations of 
compounds or DMSO for 10 min at 37 °C, malonyl-CoA was added to a final concentration 
of 50 µM to start the reaction. Absorbance at 340 nm was measured every minute for 20 
min. Results were analyzed and IC50s were calculated by Prism 7.0 (GraphPad, La Jolla, 
USA). Experiments were performed in duplicate of three independent experiments.  
 
E. Colony formation assay 
   Breast cancer cells were seeded in six-well plates at density of 200 cells/well and cultured 
overnight. Cells were given serial concentrations of compounds or DMSO (final 
concentration 0.5%) and cultured for 14 days. Generated colonies were washed by PBS, 
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fixed in 100% methanol and stained with 0.5% crystal violet in 25% methanol. Excess dye 
was removed by wash the plates with water. Colonies were manually counted. 
Concentration-response curves and respective IC50 values were calculated using Prism 7.0. 
Experiments were performed in triplicate wells for each condition and repeated at least 
three times. 
 
F. Methylene blue assay 
   Breast cancer cells were seeded in 96 well plates at density of 2000 cells/well and 
cultured overnight.  Serial concentrations of compounds or DMSO were given to treat the 
cells and cells were cultured for 3 days. Media was then removed, and cells were washed 
with saline and fixed in 100% methanol. Each well was stained with 1% w/v methylene 
blue in 10 mM borate buffer (pH 8.5) and allow incubation for 30 min. After removing 
excess dye and washing the cells with 10 mM borate buffer (pH8.5), 100 µL 1:1 (v/v) 100% 
ethanol: 100 mM HCl mixture was added to each well to release dye. Plates were gently 
shaken and read the absorbance at 650 nm. Concentration-response curves and respective 
IC50 values were calculated using Prism 7.0. Experiments were performed in triplicate 
wells for each condition and repeated at least three times. 
 
G.  Real-time quantitative PCR analysis  
   rt-qPCR was performed as described previously [23, 24]. Briefly, treated cells were 
harvested, and total RNA was extracted using PureLink RNA Mini Kit (Life technologies, 
Grand Island, NY). Total cellular RNA then was reverse transcribed into complementary 
DNA (cDNA) by using iScrpt cDNA synthesis kit (Bio-Rad, Hercules, CA). Rt-qPCR was 
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performed using SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) on 
StepOnePlus real time PCR system. Experiments were performed in triplicate. 
 
H. Immunofluorescence imaging  
   Breast cancer cells were seeded in Nunc Lab-Tek II Chamber Slide (Thermo Scientific, 
Rockford, IL) at density of 50,000 cells/well and treated with 10 µM lansoprazole or 
DMSO twice a day for 3 days. Cells were washed with PBS and fixed with 50%:50% (v/v) 
Acetone/Methonal at room temperature for 10 minutes. Cells were permeabilized using 1 
ml Triton X-100/PBS (0.5% v/v). Non-specific protein binding was blocked with 1 ml of 
BSA (1% v/v). Primary γ-H2AX antibody (diluted 1:500 in 1% BSA; Millipore) was added 
to each well for one-hour incubation at room temperature. Followed by secondary Anti-
mouse-IgG-FITC antibody (diluted 1:500 in 1% BSA, Sigma) for 45 minutes at room 
temperature in the dark and washed twice with PBS. The cells were counter stained with 
DAPI and stored in the dark at 4 °C before viewing on a confocal microscope [24]. 
 
I. Host cell reactivation NHEJ assay  
   The host cell reactivation NHEJ assay was carried out as previously described[24] with 
minor modifications. Briefly, 1 × 104 cells were seeded in 24-well plates, cultured 
overnight and then treated with 10 µM lansoprazole or DMSO twice a day for 3 days before 
transfected with 400 ng linearized or intact pGL3-luc firefly luciferase plasmids using 
Lipofectamine 2000 (Invitrogen). pGL3-luc plasmid was linearized by HindIII digestion, 
and linearization was verified by DNA agarose gel electrophoresis before transfection. 400 
ng pRL-TK (Promega) plasmid which encodes renilla luciferase was co-transfected as a 
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control for transfection efficiency. 8 hours after transfection, cells were harvested and 
assayed for luciferase activity with Dual Luciferase Assay (Promega) on a luminometer. 
Firefly luciferase signal were normalized to renilla luciferase signal in each group. Overall 
NHEJ activity was calculated by firefly luciferase activity from cells transfected with 
linearized plasmid relative to cells transfected with intact plasmid. Experiments were 
performed in triplicate. 
 
J. Flow cytometry assay 
   Breast cancer cells were seed in 6-well plates at 2 × 105 cells/well and followed by 3-day 
treatment with 10 µM lansoprazole or DMSO twice a day. To detect apoptosis, cells were 
collected and stained with Annexin V-FITC apoptosis detection kit (Millipore, Billerica, 
MA). For cell cycle analysis, cells were fixed with ice cold 70% ethanol overnight and 
counter stained with propidium iodide (PI) for 30 min in the dark. Apoptosis and cell cycles 
were analyzed by flow cytometry.  
 
K. Combination studies 
   Combined effects of lansoprazole and doxorubicin were determined using colony 
formation assays. After concentration-response curves and respective IC50 values were 
obtained from single drug treatments, three combinations with different constant potency 
ratios (IC50 Lansoprazole/IC50 Doxorubicin) at 1:1, 1:3, and 3:1 were tested. For each potency ratio, 
combination index (CI) of different fractional effect was calculated for synergistic effects 
using isobologram and combination-index analysis. Experiments were performed in 
triplicate wells for each condition and repeated at least three times. 
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L. Isobologram and combination-index analysis 
   Data obtained from colony formation assay were used to determine drug synergy by 
isobologram analysis and combination-index analysis developed by Greco and Chou [55-
58]. Isobolograms were constructed for defined growth inhibiting effects of two drugs. The 
line of additivity was constructed by connecting two points with the same level of growth 
inhibition generated as single agent. Concentrations of the two drugs used in combination 
to provide the same effect are shown in the same plot. Synergy, additivity, or antagonism 
is indicated when this point is located below, on, or above the line, respectively. The 








where CA,X and CB,X are the concentration of drug A and B used in combination to produce 
an effect x. ICX,A and ICX,B are the corresponding concentrations of drug A and B that 
produce the same effect as a single agent. CI = 1 indicates an additive effect between two 
drugs, whereas CI < 1 or CI> 1 indicates synergy or antagonism, respectively. 
 
M. Ionize irradiation 
   1×106 breast cancer cells were seeded in 100 mm culture dish and treated with 10 µM 
lansoprazole or DMSO twice a day for 3 days. Cells were then suspended and plated in 6-
well plates at density of 200 cells/well. Pre-treated group and control group received a 
serial dose of ionize irradiation and cultured for 14 days. Generated colonies were fixed, 
stained and counted manually. Concentration-response curves and respective IC50 values 
were calculated using Prism 7.0. Experiments were performed in triplicate wells for each 
condition and repeated at least three times.
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Results 
A. PPIs inhibit FASN holoenzyme activity 
   In a previous study, it was reported that the FDA-approved PPIs inhibited the activity of 
recombinant FASN TE domain in a dose-dependent manner in vitro [46]. It is necessary to 
determine whether FASN holoenzyme activity is also inhibited by PPIs in breast cancer 
cells. For this purpose, I performed NADPH oxidation assay using lysate from MCF7 cells, 
which expressed high levels of endogenous FASN. The assay is based on FASN’s ability 
to utilize NADPH as reducing agent during lipid synthesis. Thus, incremental decrease in 
NADPH levels represents on-going FASN holoenzyme activity. As shown in Figure 1 and 
Table 1, all four PPIs inhibited FASN activity in a dose-dependent manner with IC50 
ranging from ~6 to 18 µM. Lansoprazole and rabeprazole showed superior potency than 
omeprazole and pantoprazole. These observations indicate that PPIs can inhibit full length 













Figure 1: PPIs inhibited FASN holoenzyme activity. (A) Dose dependent curves obtained 
from NADPH oxidation assay for lansoprazole, omeprazole, pantoprazole, and rabeprazole. 
(B) IC50 of FASN activity inhibited by each PPI. Each data point represents the mean ± 
standard deviation (SD) of three independent experiments performed in duplicate. ** P < 

















PPI Structure IC50 (μM) 
Lansoprazole 
 
7.26 ± 0.65 
Omeprazole 
 
16.99 ± 3.73 
Pantoprazole 
 
18.36 ± 1.67 
Rabeprazole 
 
6.65 ± 0.91 
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B. PPIs inhibited breast cancer cell survival 
   De novo fatty acid biosynthesis has previously been shown to be necessary for survival 
of breast cancer cells and inhibition of FASN induces cell death. To determine if PPIs can 
suppress breast cancer cell survival, colony formation assays were performed using MCF7, 
T47D, MDA-MB-468, and MDA-MB-231 cells in the presence or absence of serially-
diluted concentrations of the four PPIs. As shown in Figure 2, all four PPIs dose-
dependently inhibited survival of all four breast cancer cell lines.  Lansoprazole was 
consistently the most potent inhibitor in all four cell lines tested, with IC50 values of 1.28 
μM in MCF7 cells, 7.61 μM in T47D cells, 3.67 μM in MDA-MB-468 cells, and 21.35 μM 
















Figure 2: PPIs inhibited breast cancer cell survival. MCF7 (A), T47D (B), MDA-MB-468 
(C), and MDA-MB-231 (D) cells were treated with each PPI alone and survival was 
measured using a colony-formation assay. Survival curves are shown and expressed as % 
of colonies in untreated controls. The IC50 of each cell line to different PPI is shown in (E). 
Each data point represents the mean ± SD of three independent experiments performed in 
triplicate. * P < 0.05; ** P < 0.01. 
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MCF7 1.28 ± 0.74 2.80 ± 1.11 5.90 ± 0.73 9.96 ± 5.44 
T47D 7.61 ± 0.56 14.49 ± 1.80 25.87 ± 11.15 11.16 ± 0.92 
MDA-MB-468 3.67 ± 0.97 6.50 ± 0.64 8.21 ± 1.75 31.85 ± 7.63 



















C. Sensitivity to PPIs correlates with endogenous relative FASN level 
   In the colony formation assay, I observed that cell lines with higher endogenous FASN 
level were more sensitive to PPI treatment, as shown by their lower IC50 values. The IC50s 
of lansoprazole, omeprazole, and pantoprazole had strong correlations with relative FASN 
level with coefficient of determination (R2) of 0.99, 0.99, and 0.96, respectively (Figure 3). 
Rabeprazole showed less correlation with FASN expression level than the other three PPIs. 
Therefore, lansoprazole, which has the best potency and a strong correlation with 

















Figure 3: Correlation analysis of relative FASN level to IC50 of each PPI from colony 
formation assay. (A) Western blot analysis of FASN, PARP-1, and β-actin in MCF7, T47D, 
MDA-MB-468, and MDA-MB-231 cells. (B) Quantitation of relative FASN levels in four 
cell lines. FASN levels were quantitated using ImageJ and normalized to β-actin. The IC50s 
of each PPI to inhibit different breast cancer cell lines are shown in (C). Correlation 
analyses of relative FASN levels to IC50s of each PPI are shown in (D). Each point is shown 
as the average of three independent experiments ± SD. 
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D. Lansoprazole reduces mRNA and protein levels of PARP-1 
   Previous study in our lab has shown that over-expressing FASN up regulated PARP-1 
level, which contributed to DNA-damaging treatment resistance [24]. To test whether 
inhibition of FASN by lansoprazole reduces PARP-1 level, MCF7 and MDA-MB-468 cells 
were treated with various concentrations of lansoprazole for 3 days. Cells were collected 
and analyzed by western blot and rt-qPCR to detect the change of PARP-1 at mRNA and 
protein levels after lansoprazole treatment. As shown in Figure 4, PARP-1 protein 
decreased dose-dependently after lansoprazole treatment (Figure 4A). PARP-1 mRNA 
levels were also significantly reduced after treatment with 10 μM Lansoprazole for 3 days 
















Figure 4: Effect of lansoprazole treatment on PARP-1 levels in MCF7 and MDA-MB-468 
cells. (A) Western blot analysis of PARP-1 and β-actin after treating cells with different 
concentrations of lansoprazole or DMSO for 3 days. (B) Relative mRNA levels of PAPR-
1 normalized to GAPDH from rt-qPCR after treating breast cancer cells with 10 μM 
lansoprazole or DMSO for 3 days. Each bar is shown as the average of three independent 










E. Lansoprazole reduces NHEJ repair activity  
   Since inhibition of FASN by lansoprazole reduces PARP-1 level, a critical protein 
involved in DNA repair pathways, I next tested whether lansoprazole treatment could 
reduce NHEJ repair activity, the predominant form of DSB repair. Utilizing a host cell 
reactivation-based in vitro NHEJ assay, I found that NHEJ activity was significantly 
decreased after lansoprazole treatment, by 56% and 43% in MCF7 cells and MDA-MB-
468 cells, respectively (Figure 5). This observation suggests that treating breast cancer cells 


















Figure 5: Effect of lansoprazole treatment on NHEJ repair activity. MCF7 and MDA-MB-
468 cells were tested for their NHEJ activity using a host cell reactivation-based NHEJ 
assay after treating cells with 10 μM lansoprazole or DMSO for 3 days. Firefly luciferase 
activity was measured in both control and test groups of each cell line at 8 hours after 
transfection and normalized to renilla luciferase activity. NHEJ activity = (Firefly 
luciferase activity in test group) / (Firefly luciferase activity in control group) *100%. Each 












F. Lansoprazole promotes γ-H2AX accumulation 
   Due to constitutive growth signaling and defective DNA damage response, cancer cells 
exhibit “replication stress”, which leads to DNA damage and defective replication [59]. 
DSB repair is critical for maintaining genome stability even without DNA damaging agents 
or radiation. With the compromised DSB repair activity, DNA damage can accumulate [60, 
61]. Previous results suggest that FASN inhibition down-regulates PARP-1 and therefore 
decreases NHEJ activity [24]. I next examined whether knocking down or inhibiting FASN 
will affect γ-H2AX level, a marker of DNA double strand break, using western blot and 
immunofluorescence staining. After knocking down FASN using 100nM siRNA for 2 days, 
reduced PARP-1 level and increased γ-H2AX level were observed in both MCF7 and 
MDA-MB-468 cells, compared to the cells transfected with scrambled siRNA (Figure 6A). 
After treating MCF7 and MDA-MB-468 cells with 2.5 μM, 5 μM, or 10 μM lansoprazole 
for 3 days, γ-H2AX levels increased dose-dependently, compared to the low background 
levels in control cells as determined by western blot analysis (Figure 6B). In addition, I 
also performed immunofluorescence (IF) staining to visualize γ-H2AX levels in the nuclei 
of each individual cell. Increased levels of γ-H2AX foci were clearly present in 








Figure 6: Effect of FASN knock-down and lansoprazole treatment on γ-H2AX level. (A) 
Western blot analysis of γ-H2AX after knocking down FASN using siRNA in MCF7 and 
MDA-MB-468 cells for 2 days. (B) Western blot and (C) immunofluorescence staining 







G. FASN is a mediator of the anti-cancer effect of lansoprazole and olaparib 
   To determine whether FASN mediates the anti-cancer activity of PPIs, the impact of 
varying FASN levels to the sensitivity of lansoprazole was tested using a stable clone of 
MCF7 cells with FASN-overexpression (MCF7/FASN) and a stable clone of doxorubicin 
resistance MCF7 cells with FASN knockdown (M3K/shFASN), with their respective 
control vector- (MCF7/Vec) or scramble shRNA-transfected cells (M3K/Scr). If FASN 
indeed mediates the anti-cancer effect of lansoprazole, over-expressing FASN should 
increase the IC50 value of lansoprazole. On the contrary, knocking down FASN should 
decrease the IC50 value of lansoprazole since there will be less FASN target to inhibit. 
Indeed, survival assay determined by colony formation showed that elevated FASN level 
enhanced breast cancer cell survival to lansoprazole, as indicated by the significant increase 
of IC50 from 4.8 μM in empty vector-transfected cells (MCF7/Vec) to 31.34 μM in FASN-
over expressing cells (MCF7/FASN) (Figure 7A, 7C left panel). In addition, survival in 
M3k/Scr and M3k/shFASN cells were determined using methylene blue assay, since this 
pair of cells do not form colonies. As shown in Figure 7 below, while FASN expression 
was decreased, IC50 of lansoprazole significant dropped from 85.9 μM in control scramble 
shRNA-transfected cells (M3k/Scr) to 43 μM in stable FASN knockdown cells 
(M3k/shFASN) (Figure 7B, 7D left panel). These findings suggest that FASN indeed 
mediates the anti-cancer effect of lansoprazole. In addition, I tested whether FASN is a 
mediator of the anti-cancer effect of olaparib, a PARP-1 inhibitor, since FASN could 
regulate PARP-1 level (Figure 7A, 7B) [46]. Similarly, over-expressing FASN led to 
increased resistance to olaparib (Figure 7C, right panel) whereas knocking down FASN 
sensitized breast cancer cells to olaparib (Figure 7D, right panel). Taken together, these 
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results suggest that FASN is indeed a mediator of the anti-cancer effect of lansoprazole and 
























Figure 7: Effect of FASN level on sensitivity to lansoprazole and olaparib. Western blot 
analysis of FASN, PARP-1, and β-actin in (A) FASN-overexpressing cells (MCF7/FASN) 
and control vector-transfected cells (MCF7/Vec); (B) stable MCF7/AdVp3000 cells with 
FASN knockdown (M3k/shFASN) or scrambled control shRNA-transfection (M3k/Scr). 
Relative resistance factor of cell lines responds to lansoprazole and olaparib from (C) 
colony formation assay or (D) methylene blue assay. Relative resistance factor = IC50 of 
FASN up/down-regulating cells/IC50 of vector/scrambled shRNA-transfected control cells. 









H. FASN overexpression alleviates lansoprazole inhibition 
   We have shown that, in MCF7 and MDA-MB-468 cells, inhibiting FASN by lansoprazole 
reduced PARP level and NHEJ activity, eventually led to DNA damage. In this scenario, 
overexpression of ectopic FASN should be able to alleviate this pathway. As discussed 
above, over expressing and knocking down FASN decreased and increased the cellular 
sensitivity to lansoprazole treatment, respectively. To demonstrate that this change was 
through FASN inhibition, I tested PARP-1 level, NHEJ activity, and γ-H2AX level in 
vector transfected MCF7 and FASN over-expressing MCF7 cells following treatment with 
10 μM lansoprazole or DMSO for 3 days. As shown in Figure 8, FASN overexpression 
maintained the similar level of PARP-1 and NHEJ activity with vector cell control group 
after treatment, whereas PAPR-1 level and NHEJ activity of vector treated group dropped 
significantly. γ-H2AX level was also found to be lower in FASN over-expressing MCF7 
cells than vector transfected MCF7 cells. These findings provide additional evidence that 












Figure 8: Effect of FASN overexpression on cellular response to lansoprazole. FASN-
overexpressing cells (MCF7/FASN) and control vector-transfected cells (MCF7/Vec) were 
treated with DMSO or 10 μM lansoprazole for 3 days. Cells were collected for (A) western 
blot analysis of FASN, PARP-1, γ-H2AX, and β-actin, and (B) NHEJ activity using a host 
cell reactivation-based NHEJ assay. Each bar is shown as the average of three independent 












I. Lansoprazole induces apoptosis and disrupts cell cycle 
   Next, apoptosis and cell cycle distribution were analyzed using flow cytometry after 
treating MCF7 and MDA-MB-468 cells with 2.5 μM, 5 μM, 10 μM lansoprazole or DMSO 
for 3 days. As shown in Figure 9, overall apoptosis was observed in a dose-dependent way 
in both cell lines. Moreover, MCF7 cells showed G1 phase arrest (Figure 9C) while MDA-
MB-468 cells showed S phase arrest (Figure 9D) also in a dose dependent manner. Both 
G1 arrest [62-66] and S phase arrest [59, 67-70] has been reported previously to associate 
with DNA damage. These findings indicate that by inhibiting FASN, lansoprazole induces 
















Figure 9: Apoptosis and cell cycle analysis by flow cytometry after lansoprazole treatment. 
Cells were treated with different concentrations of lansoprazole or DMSO for 3 days and 
stained with annexin V or propidium iodide. Percentages of early and late apoptosis are 
shown for MCF7 (A) and MDA-MB-468 (B). The percentages of cells from G1, S, and 
G2/M phases are shown for (C) MCF7 and (D) MDA-MB-468. Each bar is shown as the 












J. Doxorubicin and lansoprazole combination promotes γ-H2AX accumulation  
   To estimate if lansoprazole can sensitize doxorubicin in combination treatment, γ-H2AX 
level was detected as marker of DNA double strand break in western blot analysis. After 
treating MCF7 and MDA-MB-468 cells with lansoprazole (10 μM) and doxorubicin (50 
nM or 200 nM), either alone or in combination for 3 days, cells exposed to both 
lansoprazole and doxorubicin had a dramatically increased γ-H2AX level compared to the 



















Figure 10: Lansoprazole promotes γ-H2AX accumulation when combined with 
doxorubicin. Western blot analyses of γ-H2AX in MCF7 (A) and MDA-MB-468 (B) cells 


















K. Doxorubicin and lansoprazole combination achieves synergistic effect 
   To further estimate the synergistic effect of lansoprazole and doxorubicin, breast cancer 
cells were treated with lansoprazole and doxorubicin in combination using colony 
formation assay. The IC50 of doxorubicin in breast cancer cells was first determined (Figure 
11A). MCF7 and MDA-MB-468 were selected for the combination study due to their 
relatively higher FASN level and better sensitivity to lansoprazole. Combination study was 
carried out in 3 different potency ratios of doxorubicin and lansoprazole: 1:3, 1:1, and 3:1. 
Combination treatments yielded significantly greater growth inhibition than either drug 
alone (Figure 11B, 11C). The isobologram analysis and combination-index analysis 
developed by Greco and Chou were used to confirm and quantify the synergism between 
lansoprazole and doxorubicin. Isobologram analysis provides a graphical presentation of 
the nature of interaction of two drugs, and combination-index analysis provides a 
quantitative measurement of the extent of drug interaction at a given effect level. 
Isobolograms were constructed for three defined effects of each drug: IC30, IC50, and IC70, 
representing 30%, 50%, and 70% growth inhibition, respectively (Figure 11D). The line of 
additivity is constructed by connecting these two points with 30%, 50% and 70% growth 
inhibition of lansoprazole and doxorubicin. Concentrations of the two drugs used in 
combination to provide the same effect are showed in the same plot. Synergy, additivity, or 
antagonism is indicated when this point is located below, on, or above the line, respectively. 
For 1:3, 1:1, and 3:1 potency ratio, at 30%, 50%, and 70% growth inhibition in MCF7 and 
MDA-MB-468 cells, all combination points are located below the line of additivity. 
Combination-index values were calculated and plotted to correlated fractional effect from 
0.3 to 0.7 to quantify synergy of drug combinations defined as additive effect (CI = 1), 
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synergism (CI < 1), and antagonism (CI > 1) (Figure 11E). CI values were summarized in 
Table 3. Both methods suggested strong synergy between doxorubicin and lansoprazole 
























Figure 11: Combination study of lansoprazole and doxorubicin. The ability of doxorubicin 
to inhibit cellular proliferation was measured by colony formation assay in (A) MCF7, 
T47D, MDA-MB468, and MDA-MB-231 cells. The ability of lansoprazole and 
doxorubicin combination to inhibit cellular proliferation at different potency ratios was 
tested in (B) MCF7 and (C) MDA-MB468 cells. Each point is shown as the average of 
three independent experiments ± SD. Isobologram analysis (D) and combination indexes 


















TABLE 3: Combination index at different fraction effect. 
  
Potency 
Ratio Combination Index 
  Lan/Dox IC30 IC35 IC40 IC45 IC50 IC55 IC60 IC65 IC70 
MCF7 
1:3 0.54 0.52 0.52 0.54 0.57 0.62 0.69 0.78 0.91 
1:1 0.68 0.58 0.52 0.48 0.45 0.44 0.45 0.47 0.50 
3:1 0.63 0.57 0.52 0.49 0.47 0.46 0.46 0.48 0.52 
MDA-MB-468 
1:3 0.36 0.39 0.42 0.46 0.49 0.53 0.56 0.61 0.66 
1:1 0.24 0.27 0.31 0.34 0.38 0.43 0.48 0.55 0.62 



















L. Lansoprazole sensitizes breast cancer cells to ionizing radiation 
   Radiation therapy is an important component in the local control of many tumor types 
including breast cancer. DNA double-strand breaks are responsible for the majority of 
ionizing radiation-induced cell killing in tumor tissue. But, the ability of breast cancer cells 
to upregulate DNA repair pathways promotes radiation resistance and tumor cell survival. 
Consequently, lansoprazole, which can reduce NHEJ activity by inhibiting FASN 
inhibition, was tested for its ability to sensitize IR treatment by examining γ-H2AX level 
and IC50 of IR using colony formation assay.  
   To detect γ-H2AX level, MCF7 and MDA-MB-468 cells were pre-treated with 10 μM 
lansoprazole or DMSO for 3 days and then treated without or with 5 Gy irradiation. Cells 
were then collected at 1 hour or 4 hours after IR.  As shown in Figure 12A, cells had similar 
γ-H2AX level with or without lansoprazole pre-treatment 1 hour after IR. But 4 hours after 
IR, lansoprazole pre-treated cells had much higher γ-H2AX level comparing to cells only 
treated with IR. 
   For survival assay, cells pre-treated with or without lansoprazole for 3 days were seeded 
in 6 well plates, followed by exposure to different doses of IR and continuous culture for 
14 days before staining and quantification of colonies formed. As shown in Figure 12B and 
Table 4, the IC50 values of IR in lansoprazole pre-treated group were significantly lower in 
both MCF7 and MDA-MB-468 cells, comparing to control-pretreated group. Thus, 






Figure 12: Lansoprazole hampers breast cancer cell γ-H2AX clearance and sensitizes IR 
treatment. (A) Western blot analyses of γ-H2AX in MCF7 and MDA-MB-468 cells treated 
with lansoprazole, IR, or in combination. (B) Dose-response curves of IR alone or 
combined with lansoprazole from colony formation assay. (C) The IC50 value of cellular 
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proliferation by IR alone or combined with lansoprazole is shown. Each point or bar is 
shown as the average of three independent experiments ± SD. * P < 0.05; ** P < 0.01; *** 
P < 0.001. (D) Representative scanned image showing different levels of colony formation 
in MCF7 and MDA-MB-468 cells treated with lansoprazole, IR, or in combination. 
 
TABLE 4: IC50 of IR in combination with or without lansoprazole. 
 DMSO Lansoprazole  
 IC50 (Gy) IC50 (Gy) P Value 
MCF7 1.96 ± 0.15 1.41 ± 0.06 0.004410959 
MDA-MB-468 2.59 ± 0.05 1.48 ± 0.05 1.01707E-05 
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Conclusions and Discussion 
   Deregulated lipid biosynthesis is a characteristic feature of cancer and plays important 
roles in tumor cell development, growth, progression, and survival. Higher enzyme levels 
and activities in the lipid synthesis pathway are found in cancer cells. FASN, the key 
enzyme in de novo lipid biosynthesis, is a promising therapeutic target for cancer. In this 
study, PPIs as FASN inhibitors were evaluated. I found that PPIs can inhibit FASN activity 
and breast cancer cell proliferation dose-dependently. My data suggest that through 
inhibition of FASN, PPIs reduced PARP-1 level and NHEJ activity, resulting in increased 
DNA damage accumulation and sensitization of breast cancer cells to doxorubicin and IR 
treatments. 
   In FASN activity assay, all four PPIs inhibited FASN activity dose-dependently at the 
micromolar level. I found that lansoprazole and rabeprazole had lower IC50s compared to 
omeprazole and pantoprazole. On the chemical structure side, omeprazole and 
pantoprazole have an extra methoxy/difluoromethoxy group on the 6th carbon of the 
benzimidazole, whereas lansoprazole and rabeprazole lack this extra moiety. This may 
indicate that the extra group on the 6th carbon can reduce the binding affinity of PPIs to 
FASN. In survival assays, lansoprazole was shown to have the highest potency in all four 
cell lines tested. On the other hand, rabeprazole, which had similar IC50 with lansoprazole 
in FASN activity assay, had much higher IC50 in survival assay. This could be due to the 
fact that rabeprazole is the most hydrophilic and water-soluble among the PPIs tested, 
making it harder to cross the cellular membrane than lansoprazole and to reach the cytosolic 
FASN protein. In addition, rabeprazole’s low membrane penetration could likely explain 
why its IC50 had a poorer correlation coefficient to relative cellular FASN level comparing 
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to lansoprazole. Thus, lansoprazole, for its consistently better performance in FASN 
activity assay, survival assay, and correlation study, was selected as the best PPI and 
evaluated in further experiments.  
   I next tested the impact of ectopically varying FASN levels on breast cancer cells’ 
sensitivity to lansoprazole. I observed higher lansoprazole IC50 in stable FASN over-
expressing MCF7 cells than control vector cells and lower lansoprazole IC50 in stable 
FASN partial knock-down M3k cells than control scramble shRNA-transfected cells. This 
seemed to be opposite to the findings from the correlation study, in which cell line with 
higher FASN level was more sensitive to lansoprazole. One possible explanation could be 
the endogenous FASN levels in parental breast cancer cell lines were the result of 
adaptation of cancer cells during mutation, development, and growth, representing roughly 
how much FASN that specific cell line requires. Thus, cell lines with higher endogenous 
FASN levels could be more dependent on de novo fatty-acid synthesis than cell lines with 
lower FASN level and as such, exhibit higher sensitivity to FASN inhibition. However, 
when FASN is ectopically over-expressed by transfection, it could give cancer cells a better 
chance to survive the treatment of FASN inhibitor, due to the extra FASN available. 
Another possibility may be that lansoprazole may have other targets in the cells and the 
overexpressed FASN may protect those targets from the effect of lansoprazole.  
   Previously, our lab has demonstrated that FASN mediated breast cancer cells’ resistance 
and survival to genotoxic treatments is through up-regulated PARP-1and NHEJ activity. In 
this work, I tested the ability of lansoprazole to reverse this resistance by inhibiting FASN 
activity, and therefore to sensitize breast cancer cells to DNA damaging insults (Figure 13). 
After treating breast cancer cells with lansoprazole, I observed significant PARP-1 level 
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reduction at both mRNA and protein levels. Lansoprazole treatment also significantly 
reduced NHEJ repair activity and increased γ-H2AX level, indicating elevated DSB 
accumulation. When combined with either doxorubicin or ionizing radiation, cells treated 
with lansoprazole had higher γ-H2AX level and lower IC50 to doxorubicin and IR than 
treated with doxorubicin or IR alone. These novel findings may suggest the possibility that 
utilizing lansoprazole, an FDA-approved OTC drug in combination therapy, has the 
potential to benefit breast cancer patients not only by reducing the dose of toxic DNA 
damaging agents or IR, but also by regaining sensitivity in resistant breast cancers.  
   A few other groups have also reported that PPIs inhibit cancer cell growth using in vitro 
and animal models. Most studies concluded that PPIs exert their anti-cancer activity 
through proton pump inhibition via the disulfide bond, not by targeting the gastric H+, K+-
ATPase, but via the neoplastic vacuolar H+-ATPase (V-ATPase), a type of proton pump 
expressed by cancer cells [71-74]. Cancer cells have unique metabolism and dysregulated 
pH compared to normal cells, known as the Warburg effect, thus up-regulated proton 
extrusion activity via V-ATPase is crucial for tumor cells to survive this unfavorable 
condition. It is believed that inhibiting V-ATPase with PPIs reduces proton extrusion and 
induces sensitization of cancer cells to chemotherapeutics. In addition, Azzarito et al. 
suggest that the low pH of tumor microenvironment is also suitable for activation of PPIs 
[53]. This mechanism seems valid to explain the anti-cancer activity of PPIs.  
   However, questions remain about this V-ATPase theory, particularly regarding the 
activation step of PPIs required for their V-ATPase inhibition activity. As we know, PPIs 
are prodrugs with alkaline properties, and must undergo two steps of protonation to become 
fully activated thiophilic sulphenamides. The pKa1 of PPIs are around 4 and pKa2 are 
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below 1. The only space in the body with a pH below 4.0 to allow selective accumulation 
and activation of PPIs is inside the gastric parietal cells, the traditional target of PPIs. In 
addition, once activated, PPIs become less membrane permeable, which makes it more 
difficult to transport out of parietal cells after activation. Activation of PPIs at the tumor 
microenvironment would be too slow to allow the build-up of any effective concentration 
of sulfonamide, plus PPIs activated at gastric parietal cell could not be transported to tumor 
sites, thus the majority of PPIs at the tumor site are un-activated and incapable of inhibiting 
V-ATPase, even when given orally [75-79]. These evidences beg to argue that alternative 
mechanisms to explain PPIs’ anti-cancer activity exist. On the other hand, the commercial 
cell culture media used in our studies was buffered between 7.0 to 7.4. Under these neutral 
environments, I have observed that even inactivated PPIs still exhibited anti-cancer ability. 
Previous study in our lab showed that PPI treatment did not affect the intracellular or 
extracellular pH [46]. In addition, most data reported from other groups were also 
generated using neutrally-buffered media. Even for the study which claims the low pH of 
tumor microenvironment is suitable for a full PPI activation, the lowest extracellular and 
cytosolic pH they could achieve using non-buffered media was around 6.5, which is still 
much higher than necessary for PPI activation [53]. In reports using animal models where 
PPIs were given to mice via intraperitoneal or intravenous injection which would not allow 
activation at the stomach, anti-tumor activity was also observed. Our study here presents a 
novel mechanism by which PPIs could sensitize breast cancer cells without protonating 
activation, namely via targeting FASN. 
   There are several experiments that could be performed as a follow-up to this work. Firstly, 
we could perform combination study of lansoprazole with either doxorubicin or IR in 
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mouse xenograft tumor models. We will determine if lansoprazole also reduces the protein 
and mRNA level of PARP-1 in xenograft tumors as it did in vitro. Secondly, we will test 
the optical isomers, derivatives, and metabolites of PPIs to search for compounds with 
higher potency towards FASN inhibition. Thirdly, we will determine if there is any 
synergistic effect between lansoprazole and PARP inhibitors to sensitize breast cancer cells 
to DNA damaging treatment, based on our data suggesting they could function in the same 
pathway (Figure 13). Finally, we will attempt to co-crystalize PPIs with FASN TE domain 
to map out the specific interaction between FASN and PPIs, which would provide basis for 













Figure 13: Schematic representation of the proposed mechanism by which PPIs, via FASN 
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